ReviewJournal of nanobiotechnology2026
Navigating a thorny path: oral nanomedicines for the precision management of radiation-induced intestinal injury.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Radiation-induced intestinal injury (RIII) is a severe complication that significantly compromises the quality of life and treatment outcomes in patients undergoing abdominal or pelvic radiotherapy. Despite recent advances in therapeutic strategies, conventional interventions often exhibit limited efficacy due to poor targeting, systemic side effects, and the complex pathophysiology of intestinal radiation damage. Oral nanomedicines have emerged as a promising platform, offering site-specific delivery, improved bioavailability, and enhanced mucosal protection, thereby holding unique advantages in the precise management of RIII. This review first provides a comprehensive overview of the molecular mechanisms underlying RIII and explores the intrinsic challenges that contribute to its therapeutic intractability. Guided by these mechanistic insights, we then discuss the rational design of oral nanomedicine systems tailored to mitigate radiation-induced intestinal damage. Furthermore, we highlight the translational potential of these nanoplatforms and introduce a novel concept-self-powered nanogenerators-for localized and sustained therapeutic modulation in RIII. Together, these strategies open new avenues for rethinking gastrointestinal radioprotection through the lens of precision nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.